

Mike Hedges AM  
Chair, Petitions Committee  
National Assembly for Wales  
Cardiff Bay  
Cardiff, CF99 1NA

3 November 2016

*Dear Mr Hedges,*

Thank you very much for your letter regarding the potential use of CA125 in ovarian cancer screening in Wales and I am delighted that the Assembly is looking at this issue.


The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), which reported its interim findings last December, looked at two possible models for ovarian cancer screening:

- Ultrasound – women received an annual ultrasound with this repeated more regularly if there were any abnormalities.
- Multimodal – women received an annual CA125 blood test, using women's existing CA125 levels as the benchmark, with additional testing, including ultrasound, if levels of CA125 were found to rise.

Initial findings suggested that there was no significant impact on mortality as a result of screening in either arm. However, the study has been extended for a further three years to allow for the data to further mature.

I have attached a briefing that goes into UKCTOCS in greater detail and please let me know if I can provide anything further.

Yours sincerely,



Annwen Jones  
Chief Executive

**Board of Trustees:**

Joanna Barker MBE D.Litt (Chairman)  
Mike Holt (Honorary Treasurer)  
Lisa Attenborough  
Sonya Branch  
Margaret Chamberlain  
Emma Kane  
Charlie Parker

**Patrons:**

Professor Sir Kenneth Calman KCB MD FRCS FRSE  
Dame Janet Gaymer DBE QC

**Chief Executive:**  
Annwen Jones

**2 Angel Gate**

City Road  
London EC1V 2PT  
T : 020 7923 5470  
E : [info@targetovariancancer.org.uk](mailto:info@targetovariancancer.org.uk)  
[www.targetovariancancer.org.uk](http://www.targetovariancancer.org.uk)